Maverick Capital Ltd. Buys 9,227 Shares of LivaNova PLC $LIVN

Key Points

• Maverick Capital Ltd. increased its stake in LivaNova PLC by 140.1%, acquiring an additional 9,227 shares, bringing its total holdings to 15,813 shares valued at $621,000.
• Several institutional investors have significantly boosted their positions in LivaNova, with UMB Bank n.a. increasing its stake by 340.5%, showcasing strong institutional interest in the company.
• Analysts have raised their price targets for LivaNova, with the consensus rating categorized as a "Buy" and an average price target of $59.71.

Maverick Capital Ltd. grew its stake in shares of LivaNova PLC (NASDAQ:LIVN - Free Report) by 140.1% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 15,813 shares of the company's stock after acquiring an additional 9,227 shares during the quarter. Maverick Capital Ltd.'s holdings in LivaNova were worth $621,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in LIVN. Mariner LLC boosted its holdings in shares of LivaNova by 8.4% during the 4th quarter. Mariner LLC now owns 5,741 shares of the company's stock valued at $266,000 after acquiring an additional 446 shares during the last quarter. Hsbc Holdings PLC boosted its holdings in shares of LivaNova by 25.5% during the 4th quarter. Hsbc Holdings PLC now owns 5,876 shares of the company's stock valued at $272,000 after acquiring an additional 1,193 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its holdings in shares of LivaNova by 11.5% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 37,180 shares of the company's stock valued at $1,722,000 after acquiring an additional 3,839 shares during the last quarter. Northern Trust Corp boosted its holdings in shares of LivaNova by 11.2% during the 4th quarter. Northern Trust Corp now owns 703,019 shares of the company's stock valued at $32,557,000 after acquiring an additional 70,630 shares during the last quarter. Finally, Jane Street Group LLC boosted its holdings in shares of LivaNova by 45.5% during the 4th quarter. Jane Street Group LLC now owns 193,826 shares of the company's stock valued at $8,976,000 after acquiring an additional 60,613 shares during the last quarter. Hedge funds and other institutional investors own 97.64% of the company's stock.

Analysts Set New Price Targets

LIVN has been the topic of a number of recent analyst reports. Barclays raised their price target on shares of LivaNova from $55.00 to $58.00 and gave the company an "equal weight" rating in a report on Thursday, August 21st. Wolfe Research upgraded shares of LivaNova from a "peer perform" rating to an "outperform" rating and set a $60.00 price objective on the stock in a research note on Tuesday, May 20th. Wall Street Zen upgraded shares of LivaNova from a "buy" rating to a "strong-buy" rating in a research note on Saturday, August 9th. Finally, Needham & Company LLC reiterated a "buy" rating and issued a $64.00 price objective on shares of LivaNova in a research note on Wednesday. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has issued a Hold rating to the company. According to MarketBeat, the stock presently has an average rating of "Buy" and a consensus target price of $59.71.

LivaNova Stock Performance

Shares of NASDAQ:LIVN traded down $0.18 during trading on Friday, hitting $57.97. The company's stock had a trading volume of 958,459 shares, compared to its average volume of 633,219. LivaNova PLC has a 12 month low of $32.48 and a 12 month high of $58.42. The firm has a market cap of $3.17 billion, a price-to-earnings ratio of -14.90 and a beta of 0.97. The company has a 50-day moving average of $48.67 and a 200-day moving average of $43.68. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.29 and a quick ratio of 1.09.

LivaNova (NASDAQ:LIVN - Get Free Report) last released its earnings results on Wednesday, August 6th. The company reported $1.05 EPS for the quarter, topping analysts' consensus estimates of $0.84 by $0.21. LivaNova had a negative net margin of 16.13% and a positive return on equity of 14.57%. The company had revenue of $352.50 million for the quarter, compared to analysts' expectations of $332.20 million. During the same quarter last year, the business earned $0.93 EPS. The firm's revenue was up 10.6% compared to the same quarter last year. On average, sell-side analysts expect that LivaNova PLC will post 2.85 earnings per share for the current year.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.